<DOC>
	<DOCNO>NCT02685098</DOCNO>
	<brief_summary>Patients undergo semi-elective knee amputation complication associate atherosclerotic limb ischemia receive intra-muscular injection allogeneic Mesenchymal Stromal Cells leg point amputation prevent ischemic wound complication surgery decrease incidence conversion knee knee amputation .</brief_summary>
	<brief_title>A Clinical Histological Analysis Mesenchymal Stem Cells Amputation</brief_title>
	<detailed_description>This phase I single center open label trial study enroll sixteen patient require semi-elective knee amputation ( BKA ) within 30 day period non-infectious complication related critical limb ischemia ( CLI ) . After enrollment patient randomize BKA 3,7,14 , 21 day MSC administration . The investigational treatment use allogeneic bone marrow derive mesenchymal stem cell point care . Allogeneic MSCs inject thigh muscle gastrocnemius muscle sixteen patient undergo BKA . Through review treatment related adverse event 6 month test hypothesis allogeneic MSCs result significant cardiovascular , respiratory , infectious treatment related adverse event . Through exploratory investigation ass efficacy MSCs promoting freedom gangrene , conversion AKA , death BKA .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Pathologic Processes</mesh_term>
	<criteria>1 . Be ≥ 40 ≤80 year age . 2 . Patients require knee amputation , determine independent vascular specialist , rest pain , nonsuppurative gangrene , ulceration due limb ischemia . 3 . Resting Ankle Brachial Index &lt; 0.55 TBI &lt; 0.40 . 4 . Ulceration gangrene distal malleoli ( allow adequate length ATM 4 injection 4 cm . apart ) 5 . BKA safely perform 30 day screen , determine independent vascular orthopedic surgeon . 6 . Females childbearing potential must willing use one form birth control duration study . Female participant must undergo blood urine pregnancy test screening . 1 . Evidence infection . Suppurative gangrene : purulence emanate gangrenous area , without compression . Spreading cellulitis : proximal progression erythema wound within 24 hour . Systemic manifestation infection : WBC &gt; 11.5k ( antibiotic therapy &gt; 24 hour ) , increase oxygen requirement pulmonary failure , pressor support , change creatinine &gt; 50 % baseline 2 . Patients pregnant , plan become pregnant next 12 month , lactate . 3 . Venous stasis disease lymphedema . 4 . An HbA1C level &gt; 10 % 5 . Significant hepatic dysfunction ( ALT AST great 2 time normal ) . 6. eGFR &lt; 30mL/min 7 . CHF hospitalization within last 1 month prior enrollment . * 8 . Acute coronary syndrome last 1 month prior enrollment . * 9 . HIV positive , active HBV HCV . 10 . History cancer within last 5 year , except basal cell skin carcinoma 11 . Any bleeding diathesis define INR ≥ 2.0 ( anticoagulation therapy ) history platelet count le 70,000 hemophilia . 12 . Inability provide write informed consent due cognitive language barrier ( interpreter permit ) . 13 . Concurrent enrollment another clinical investigative trial . 14 . Any condition require immunosuppressant medication ( e.g. , treatment organ transplant , psoriasis , Crohn 's disease , alopecia areata ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stem cell</keyword>
	<keyword>MSCs</keyword>
	<keyword>Mesenchymal</keyword>
	<keyword>Amputation</keyword>
	<keyword>BKA</keyword>
	<keyword>knee amputation</keyword>
	<keyword>CHAMP</keyword>
</DOC>